{"id":36685,"date":"2025-07-04T15:42:20","date_gmt":"2025-07-04T07:42:20","guid":{"rendered":"https:\/\/flcube.com\/?p=36685"},"modified":"2025-07-04T15:42:21","modified_gmt":"2025-07-04T07:42:21","slug":"sumitomo-pharmas-xenleta-approved-in-china-for-community-acquired-pneumonia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36685","title":{"rendered":"Sumitomo Pharma&#8217;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment"},"content":{"rendered":"\n<p>Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.<\/p>\n\n\n\n<p><strong>Mechanism of Action<\/strong><br>Lefamulin binds to both the A-site and P-site of bacterial ribosomes, blocking the proper positioning of tRNA and peptide transfer, thereby inhibiting bacterial protein synthesis. This dual-site binding mechanism not only enhances the drug&#8217;s binding affinity to ribosomes but also makes it less prone to inducing resistance. The tricyclic core and C-14 side chain structure of lefamulin further stabilize its binding to ribosomes. This gives it potent antibacterial activity against various pathogens, including drug-resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDR-SP (multidrug-resistant Streptococcus pneumoniae), as well as atypical pathogens like Mycoplasma pneumoniae, which exhibits over 80% resistance to macrolide antibiotics.<\/p>\n\n\n\n<p><strong>Development and Rights Acquisition<\/strong><br>Originally developed by Nabriva Therapeutics, Sumitomo Pharmaceuticals (Suzhou) acquired the exclusive development and commercial rights to lefamulin for Mainland China, Hong Kong, Macau, and Taiwan (Greater China) in May 2021. Sumitomo Pharma subsequently obtained the Greater China rights to the drug from Nabriva in July 2023.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36686,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,577],"class_list":["post-36685","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-product-approvals","tag-sumitomo-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sumitomo Pharma&#039;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36685\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sumitomo Pharma&#039;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment\" \/>\n<meta property=\"og:description\" content=\"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36685\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T07:42:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T07:42:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sumitomo Pharma&#8217;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment\",\"datePublished\":\"2025-07-04T07:42:20+00:00\",\"dateModified\":\"2025-07-04T07:42:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0407.webp\",\"keywords\":[\"Product approvals\",\"Sumitomo Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36685#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36685\",\"name\":\"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0407.webp\",\"datePublished\":\"2025-07-04T07:42:20+00:00\",\"dateModified\":\"2025-07-04T07:42:21+00:00\",\"description\":\"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36685\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0407.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36685#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sumitomo Pharma&#8217;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36685","og_locale":"en_US","og_type":"article","og_title":"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment","og_description":"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.","og_url":"https:\/\/flcube.com\/?p=36685","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T07:42:20+00:00","article_modified_time":"2025-07-04T07:42:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36685#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36685"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sumitomo Pharma&#8217;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment","datePublished":"2025-07-04T07:42:20+00:00","dateModified":"2025-07-04T07:42:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36685"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36685#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","keywords":["Product approvals","Sumitomo Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36685#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36685","url":"https:\/\/flcube.com\/?p=36685","name":"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36685#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36685#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","datePublished":"2025-07-04T07:42:20+00:00","dateModified":"2025-07-04T07:42:21+00:00","description":"Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for Xenleta (lefamulin). The drug, a truncated amphotericin antibiotic, was awarded priority review status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). It is approved for the treatment of community-acquired pneumonia (CAP) as a Category 4 chemical generic drug. Previously, Xenleta was approved as a Category 5.1 chemical drug (imported new drug) in November 2023 under Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36685#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36685"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36685#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","width":1080,"height":608,"caption":"Sumitomo Pharma's Xenleta Approved in China for Community-Acquired Pneumonia Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36685#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sumitomo Pharma&#8217;s Xenleta Approved in China for Community-Acquired Pneumonia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36685"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36685\/revisions"}],"predecessor-version":[{"id":36688,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36685\/revisions\/36688"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36686"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}